Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
9m agoMGE Energy, Inc. Prices Public Offering of 3,300,331 Shares of Common Stock
9m agoTravere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
36m agoInnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
36m agoMcEwen Generates Strong Q1 Results & Advances Multi-Asset Growth Strategy; Net Income $33.4M ($0.56 per Share) vs. Net Loss $6.3M ($0.12 per Share) in Q1 2025; Internally Funding Key Projects to Double Production by 2030
36m agoAvnet opens new integration facility in Singapore to strengthen Asia-Pacific supply chain resilience
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

About

Travere Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Today
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 5 2026
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Apr 27 2026
Travere Therapeutics to Report First Quarter 2026 Financial Results
Apr 14 2026
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Apr 13 2026
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

Community Chat

Ask AI

6ix6ixAIEvents